RxDoctor Payments Data

Kellie Gromacki

Family · Erie, PANPI 1427786920

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $470 of the $549 with a category attached, or 85.6%. 7 manufacturers reported payments, led by Johnson & Johnson at 43.7% of the total.

$549in general payments, 2019–2025

Across 16 payments — averaging $34.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$240
  • AbbVie$92
  • Janssen Scientific Affairs, LLC$80
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$52
  • Pfizer$52
  • Takeda Pharmaceuticals U.S.A., Inc.$17
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$47086%
  • Education$7914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$549 in reported general payments places this provider in the 60th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$29,819
Medicare patients
255
Services billed
300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase31$59,378
LinzessLinaclotide67$54,453
Dexlansoprazole DrDexlansoprazole62$22,233
DexilantDexlansoprazole30$15,063
Mesalamine18$14,318
Famotidine538$7,338
Colestipol Hcl68$7,269
Pantoprazole Sodium512$6,600
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates83$5,266
Lubiprostone12$4,133
Balsalazide Disodium19$3,824
Esomeprazole Magnesium120$3,086
Ursodiol12$2,044
Omeprazole119$2,039
Lansoprazole41$1,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$92$113,83198 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$17$15,06330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,717 family providers in Pennsylvania.

Other family in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →